Cited by 190Glioma Diagnosis and TreatmentNanoparticle-Based Drug DeliveryDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Phase I Study of GRN1005 in Recurrent Malignant Glioma

Drappatz, Jan, Brenner, Andrew, Wong, Eric T., Eichler, April, Schiff, David, Groves, Morris D., Mikkelsen, Tom, Rosenfeld, Steve, Sarantopoulos, John, Meyers, Christina A., Fielding, Robert M., Elian, Kelly, Wang, Xiaolin, Lawrence, Betty, Shing, Mona, Kelsey, Stephen, Castaigne, Jean Paul, Wen, Patrick Y.·2013·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-12-2481

Open this paper in CoChat — free account

Abstract

PURPOSE: GRN1005 is a peptide-drug conjugate with the ability to penetrate the blood-brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor-related protein-1. We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma. METHODS: Patients received GRN1005 by intravenous infusion every 3 weeks. Doses were escalated using a modified Fibonacci scheme. Study objectives included safety, tolerability, identification of the maximum tolerated dose (MTD), pharmacokinetics, and preliminary evidence of efficacy. Tumor extracted from patients undergoing surgery following administration of GRN1005 was analyzed to determine whether therapeutic concentrations of GRN1005 were achieved. RESULTS: Sixty-three patients received GRN1005 at doses of 30 to 700 mg/m(2) every 3 weeks. Therapy was well tolerated with neutropenia, leucopenia, and fatigue as the most frequent drug-associated grade 3/4 or higher toxicities. The MTD was 650 mg/m(2) every 3 weeks. Dose-limiting toxicities were grade 3 mucositis and grade 4 neutropenia. There was no evidence of central nervous system toxicity or antibody production. Pharmacokinetic analysis showed that exposure to GRN1005 was dose proportional. We observed one complete and two partial responses. Eight of 27 patients dosed ≥ 420 mg/m(2) had stable disease, which lasted a median of 51 days. Therapeutic concentrations of GRN1005 and free paclitaxel were shown in tumor tissue of surgical patients dosed with ≥ 200 mg/m(2). CONCLUSION: GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m(2) every 3 weeks.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-2481

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Malignant Gliomas in Adults
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Self-citation
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,516
Self-citation
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M. A., Butman, J. A., Camphausen, K. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,567
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.
Aronen, H. J., Gazit, I. E., Louis, D. N., Buchbinder, B. R., Pardo, F. S., Weisskoff, R. M., Harsh, G. R., Cosgrove, G. R., Halpern, E. F., & Hochberg, F. H. (1994) · Radiology · doi:10.1148/radiology.191.1.8134596 · Cited by 905
LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout Studies
Lillis, A. P., Van Duyn, L. B., Murphy-Ullrich, J. E., & Strickland, D. K. (2008) · Physiological Reviews · doi:10.1152/physrev.00033.2007 · Cited by 669
Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557
Self-citation
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518

Show all 51 references

Sorted by citations

The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C., Ferraro, G. B., & Jain, R. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,919
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citation
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C. E., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 859
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Treatment of Brain Metastases
Lin, X., & DeAngelis, L. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9503 · Cited by 452
Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery
Oller‐Salvia, B., Sánchez‐Navarro, M., Giralt, E., & Teixidò, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 463
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
Brain-targeted drug delivery by manipulating protein corona functions
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334
Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma
Oberoi, R. K., Parrish, K. E., Sio, T. T. W., Mittapalli, R. K., Elmquist, W. F., & Sarkaria, J. N. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov164 · Cited by 283
ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Kumthekar, P., Tang, S.-C., Brenner, A. J., Kesari, S., Piccioni, D. E., Anders, C., Carrillo, J., Chalasani, P., Kabos, P., Puhalla, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3258 · Cited by 250
Self-citation
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
Hoppenz, P., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00571 · Cited by 248
Brain penetrating peptides and peptide–drug conjugates to overcome the blood–brain barrier and target CNS diseases
Zhou, X., Smith, Q. R., & Liu, X. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1695 · Cited by 229
Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Fu, C. S., Yu, L., Miao, Y., Liu, X., Yu, Z., & Wei, M. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.020 · Cited by 221
Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma
Jiang, Y., Zhang, J., Meng, F., & Zhong, Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b05265 · Cited by 201
Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges
Komin, A., Russell, L. M., Hristova, K. A., & Searson, P. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.002 · Cited by 193
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy
Upton, D. H., Ung, C., George, S. M., Tsoli, M., Kavallaris, M., & Ziegler, D. S. (2022) · Theranostics · doi:10.7150/thno.69682 · Cited by 182
Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
Zhang, D. Y., Dmello, C., Chen, L., Arrieta, V. A., González-Buendía, E., KANE, J. R., Magnusson, L. P., Baran, A. H., James, C. D., Horbinski, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2182 · Cited by 176
Peptide–drug conjugate-based novel molecular drug delivery system in cancer
Zhu, Y., Tang, K., & Lv, J. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.07.001 · Cited by 157
On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site
Vrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 157
Drug delivery strategies to enhance the permeability of the blood–brain barrier for treatment of glioma
Zhang, F., Xu, C., & Liu, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s79592 · Cited by 147
Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma
Harder, B. G., Blomquist, M. R., Wang, J., Kim, A. J., Woodworth, G. F., Winkles, J. A., Loftus, J. C., & Tran, N. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00462 · Cited by 153
Antibody therapies in CNS diseases
Freskgård, P., & Urich, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.014 · Cited by 144
Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours
Ferraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231479 · Cited by 131
Retro-Inverso Isomer of Angiopep-2: A Stable d -Peptide Ligand Inspires Brain-Targeted Drug Delivery
Wei, X., Zhan, C., Chen, X., Hou, J., Xie, C., & Lu, W. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500086e · Cited by 127
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma
Narsinh, K. H., Perez, E., Haddad, A. F., Young, J. S., Savastano, L. E., Villanueva-Meyer, J. E., Winkler, E. A., & de Groot, J. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01338-x · Cited by 140
Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate model
Horodyckid, C., Canney, M. S., Vignot, A., Boisgard, R., Drier, A., Huberfeld, G., François, C., Prigent, A., Santin, M. D., Adam, C., et al. (2016) · Journal of neurosurgery · doi:10.3171/2016.3.jns151635 · Cited by 124
Novel delivery methods bypassing the blood-brain and blood-tumor barriers
Hendricks, B. K., Cohen‐Gadol, A., & Miller, J. C. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.1.focus14767 · Cited by 124
ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
Regina, A., Demeule, M., Tripathy, S., Lord-Dufour, S., Currie, J.-C., Iddir, M., Annabi, B., Castaigne, J.-P., & Lachowicz, J. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0399 · Cited by 112
Self-citation
Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties
Demeule, M., Beaudet, N., Régina, A., Besserer‐Offroy, É., Murza, A., Tétreault, P., Belleville, K., Ché, C., Larocque, A., Thiot, C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70647 · Cited by 122
Self-citation
Agile delivery of protein therapeutics to CNS
Yi, X., Manickam, D. S., Brynskikh, A. M., & Kabanov, A. V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.017 · Cited by 116
Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis
Razzak, R. A., Florence, G. J., & Gunn‐Moore, F. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123108 · Cited by 118
Targeting specific cells in the brain with nanomedicines for CNS therapies
Zhang, F., Lin, Y.-A., Kannan, S., & Kannan, R. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.013 · Cited by 113
Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety
He, R., Finan, B., Mayer, J. P., & DiMarchi, R. D. (2019) · Molecules · doi:10.3390/molecules24101855 · Cited by 110
Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions
Nhàn, N. T. T., Yamada, T., & Yamada, K. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612931 · Cited by 114
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Munnink, T. H. O., Enting, R. H., den Dunnen, W. F. A., Heesters, M. A. A. M., Kruyt, F. A. E., Hooge, M. N. L., de Groot, J. C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154401 · Cited by 104
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Mair, M. J., Bartsch, R., Rhun, É. L., Berghoff, A. S., Brastianos, P. K., Cortés, J., Gan, H. K., Lin, N., Lassman, A. B., Wen, P. Y., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00756-z · Cited by 109
Self-citation
Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain
Wu, J. R., Hernández, Y. M., Miyasaki, K. F., & Kwon, E. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114820 · Cited by 108
Peptide-Drug Conjugates: A New Hope for Cancer Management
Chavda, V. P., Solanki, H. K., Davidson, M., Apostolopoulos, V., & Bojarska, J. (2022) · Molecules · doi:10.3390/molecules27217232 · Cited by 100
Receptor-Mediated Drug Delivery Systems Targeting to Glioma
Wang, S., Meng, Y., Li, C., Qian, M., & Huang, R. (2015) · Nanomaterials · doi:10.3390/nano6010003 · Cited by 94
Drug delivery and release systems for targeted tumor therapy
Böhme, D., & Beck‐Sickinger, A. G. (2015) · Journal of Peptide Science · doi:10.1002/psc.2753 · Cited by 94
Transcellular brain drug delivery: A review on recent advancements
Azarmi, M., Maleki, H., Nikkam, N., & Malekinejad, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119582 · Cited by 96
Peptide-decorated polymeric nanomedicines for precision cancer therapy
Sun, H., Dong, Y., Feijén, J., & Zhong, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.029 · Cited by 94
How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases
Angeli, E., Nguyen, T. T., Janin, A., & Bousquet, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010022 · Cited by 93
Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges
Parrasia, S., Szabó, I., Zoratti, M., & Biasutto, L. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00523 · Cited by 95
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells
Gilad, Y., Firer, M. A., & Gellerman, G. (2016) · Biomedicines · doi:10.3390/biomedicines4020011 · Cited by 87
Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles
Wang, L., Hao, Y., Li, H., Zhao, Y., Meng, D., Li, D., Shi, J., Zhang, H., Zhang, Z., & Zhang, Y. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1025077 · Cited by 87
Biomimetic drug-delivery systems for the management of brain diseases
Chen, Y., Wei, C., Lyu, Y., Chen, H., Jiang, G., & Gao, X. (2019) · Biomaterials Science · doi:10.1039/c9bm01395d · Cited by 89
Recent advances in nanoparticle-based approaches for the treatment of brain tumors: Opportunities and challenges
Ahamed, J., Gowda, B. H. J., Almalki, W. H., Gupta, N., Sahebkar, A., & Kesharwani, P. (2023) · European Polymer Journal · doi:10.1016/j.eurpolymj.2023.112111 · Cited by 84
Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies
Balça-Silva, J., Matias, D., do Carmo, A., Sarmento‐Ribeiro, A. B., Lopes, M. C., & Moura‐Neto, V. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.007 · Cited by 82
Micro‐Nanocarriers Based Drug Delivery Technology for Blood‐Brain Barrier Crossing and Brain Tumor Targeting Therapy
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review
Vogelbaum, M. A., Krivosheya, D., Borghei-Razavi, H., Sanai, N., Weller, M., Wick, W., Soffietti, R., Reardon, D. A., Aghi, M. K., Galanis, E., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa149 · Cited by 75
Self-citation
Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates
Worm, D. J., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Peptide Science · doi:10.1002/pep2.24171 · Cited by 76
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
Lindberg, J., Nilvebrant, J., Nygren, P., & Lehmann, F. (2021) · Molecules · doi:10.3390/molecules26196042 · Cited by 72
Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes
Shi, Y., Jiang, Y., Cao, J., Yang, W., Zhang, J., Meng, F., & Zhong, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.034 · Cited by 72
Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches
Yeini, E., Ofek, P., Albeck, N., Ajamil, D. R., Neufeld, L., Eldar‐Boock, A., Kleiner, R., Vaskovich‐Koubi, D., Koshrovski‐Michael, S., Dangoor, S. I., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000124 · Cited by 70
Promising Approaches to Circumvent the Blood–Brain Barrier: Progress, Pitfalls and Clinical Prospects in Brain Cancer
Papademetriou, I. T., & Porter, T. M. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.48 · Cited by 70
Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Kimura, S., & Harashima, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121216 · Cited by 65
Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics
Markowicz-Piasecka, M., Markiewicz, A., Darłak, P., Sikora, J., Adla, S. K., Bagina, S., & Huttunen, K. M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01228-5 · Cited by 68
Current progress and remaining challenges of peptide–drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?
Wang, D., Yin, F., Li, Z., Zhang, Y., & Chen, S. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03277-2 · Cited by 72
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging
Ayo, A., & Laakkonen, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040481 · Cited by 67
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Wu, M., Huang, W., Yang, N., & Liu, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00347-1 · Cited by 59
Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes
Vetter, V. C., & Wagner, E. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.013 · Cited by 61
The Matricellular Receptor LRP1 Forms an Interface for Signaling and Endocytosis in Modulation of the Extracellular Tumor Environment
Gool, B. V., Dedieu, S., Emonard, H., & Roebroek, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00271 · Cited by 59
Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma
Branco, F., Cunha, J., Mendes, M., Vitorino, C., & Sousa, J. (2024) · ACS Nano · doi:10.1021/acsnano.4c01790 · Cited by 60
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic
Rizvi, S. F. A., Zhang, L., Zhang, H., & Fang, Q. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00269 · Cited by 57
Peptide Shuttles for Blood–Brain Barrier Drug Delivery
Sánchez‐Navarro, M., & Giralt, E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091874 · Cited by 58
Peptide-decorated nanocarriers penetrating the blood-brain barrier for imaging and therapy of brain diseases
Gao, X., Xu, J., Yao, T., Liu, X., Zhang, H., & Zhan, C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114362 · Cited by 56
Recent Uses of Lipid Nanoparticles, Cell-Penetrating and Bioactive Peptides for the Development of Brain-Targeted Nanomedicines against Neurodegenerative Disorders
Wu, Y., & Angelova, A. (2023) · Nanomaterials · doi:10.3390/nano13233004 · Cited by 58
Breaching the Blood–Brain Tumor Barrier for Tumor Therapy
Marcucci, F., Corti, A., & Ferreri, A. J. M. (2021) · Cancers · doi:10.3390/cancers13102391 · Cited by 51
Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)
Li, F., & Tang, S.-C. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.01.004 · Cited by 47
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
Parakh, S., Nicolazzo, J. A., Scott, A. M., & Gan, H. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.718590 · Cited by 46
Development of Engineered Nanoparticles Expediting Diagnostic and Therapeutic Applications Across Blood–Brain Barrier
Sardoiwala, M. N., Kaundal, B., & Choudhury, S. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813351-4.00038-9 · Cited by 49
BBPpredict: A Web Service for Identifying Blood-Brain Barrier Penetrating Peptides
Chen, X., Zhang, Q., Li, B., Lu, C., Yang, S., Long, J., He, B., Chen, H., & Huang, J. H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.845747 · Cited by 45
Recent Advancements and Strategies for Overcoming the Blood–Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma
Tincu, C.-E., Andrițoiu, C. V., Popa, M., & Ochiuz, L. (2023) · Polymers · doi:10.3390/polym15193969 · Cited by 43
Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review
Zottel, A., Jovčevska, I., Šamec, N., & Komel, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103283 · Cited by 40
The Recent Advance of Cell-Penetrating and Tumor-Targeting Peptides as Drug Delivery Systems Based on Tumor Microenvironment
Zhang, Q., Liu, N., Wang, J., Liu, Y., Wang, K., Zhang, J., & Pan, X. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00629 · Cited by 48
Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies
ter Linden, E., Abels, E. R., van Solinge, T. S., Neefjes, J., & Broekman, M. L. D. (2024) · Cells · doi:10.3390/cells13120998 · Cited by 45
ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment
O'Sullivan, C. C., Lindenberg, M. L., Bryla, C., Patronas, N., Peer, C. J., Amiri‐Kordestani, L., Davarpanah, N. N., Gonzalez, E. M., Burotto, M., Choyke, P. L., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3972-z · Cited by 40
Nanocarrier drugs in the treatment of brain tumors
Černá, T., Stiborová, M., Adam, V., Kizek, R., & Eckschlager, T. (2016) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2015.95 · Cited by 40
Prodrugs as drug delivery system in oncology
Delahousse, J., Skarbek, C., & Paci, A. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03906-2 · Cited by 40
Peptide based drug delivery systems to the brain
Islam, Y., Leach, A. G., Smith, J. A., Pluchino, S., Coxon, C. R., Sivakumaran, M., Downing, J. R., Fatokun, A. A., Teixidò, M., & Ehtezazi, T. (2020) · Nano Express · doi:10.1088/2632-959x/ab9008 · Cited by 41
Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma
Sun, B., Li, R., Ji, N., Liu, H., Wang, H., Chen, C., Bai, L., Su, J., & Chen, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101443 · Cited by 44
Targeting Tumors with Small Molecule Peptides
Cheetham, A. G., Keith, D., Zhang, P., Lin, R., Su, H., & Cui, H. (2016) · Current Cancer Drug Targets · doi:10.2174/1568009616666151130214646 · Cited by 37
A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art
Pinkiewicz, M., Pinkiewicz, M., Walecki, J. M., & Zawadzki, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950167 · Cited by 35
Current and Investigational Drug Strategies for Glioblastoma
Ajaz, M., Jefferies, S., Brazil, L., Watts, C., & Chalmers, A. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.012 · Cited by 35
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Framework Nucleic Acid Nanomaterials for Central Nervous System Therapies: Design for Barrier Penetration, Targeted Delivery, Cellular Uptake, and Endosomal Escape
Chen, X., Luo, X., Yin, W., Cui, W., He, Y., Tian, T., & Lin, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c03945 · Cited by 39
Overcoming the blood–brain barrier in neurodegenerative disorders and brain tumours
Ebrahimi, Z., Talaei, S., Aghamiri, S., Goradel, N. H., Jafarpour, A., & Negahdari, B. (2020) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2019.0351 · Cited by 35
Targeted Glioma Therapy—Clinical Trials and Future Directions
Shikalov, A. B., Koman, I. E., & Kogan, N. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010100 · Cited by 35
Recent advances in liposomes and peptide-based therapeutics for glioblastoma treatment
Jourdain, M. A., & Eyer, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.037 · Cited by 32
Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood–Brain Barrier and Blood–Tumor Barrier
Pinkiewicz, M., Zaczyński, A., Walecki, J. M., & Zawadzki, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157050 · Cited by 36
Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases
Lim, M., Puttick, S. G., Houston, Z. H., Thurecht, K. J., Croft, P. K., Mahler, S. M., Rose, S., Jeffree, R. L., Mazzieri, R., Dolcetti, R., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061280 · Cited by 32
Engineering peptide drug therapeutics through chemical conjugation and implication in clinics
Rizvi, S. F. A., Zhang, H., & Fang, Q. (2024) · Medicinal Research Reviews · doi:10.1002/med.22046 · Cited by 30
Novel chemotherapeutics and other therapies for treating high-grade glioma
Kang, J. H., & Adamson, C. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1048332 · Cited by 27
Dendrimer-based magnetic resonance imaging agents for brain cancer
Ding, L., Lyu, Z., Dhumal, D. M., Kao, C., Bernard, M., & Peng, L. (2018) · Science China Materials · doi:10.1007/s40843-018-9323-6 · Cited by 29
Brain metastasis models: What should we aim to achieve better treatments?
Masmudi‐Martín, M., Zhu, L., Sánchez‐Navarro, M., Priego, N., Casanova-Acebes, M., Ruiz‐Rodado, V., Giralt, E., & Valiente, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.002 · Cited by 27

Authors: Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., Fielding, R. M., Elian, K., Wang, X., Lawrence, B., Shing, M., Kelsey, S., Castaigne, J. P., & Wen, P. Y.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Drappatz, Jan
Brenner, Andrew
Wong, Eric T.
Schiff, David
Mikkelsen, Tom
Sarantopoulos, John
Fielding, Robert M.
Wang, Xiaolin
Wen, Patrick Y.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2013-03-14
Volume: 19
Issue: 6
Pages: 1567-1576
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-12-2481
OpenAlex: W2111631341
Cited by: 190
References: 51
Citations by year: 2026: 11 · 2025: 16 · 2024: 15 · 2023: 16 · 2022: 22 · 2021: 15 · 2020: 17 · 2019: 19 · 2018: 12 · 2017: 6 · 2016: 15 · 2015: 18 · 2014: 7 · 2013: 1
FWCI: 6.73
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: recurrent malignant glioma, peptide-drug conjugates, LDL receptor-related protein 1, blood-brain barrier penetration, paclitaxel, maximum tolerated dose, pharmacokinetics, dose-limiting toxicity
MeSH terms: Adult, Aged, Antineoplastic Agents, Blood-Brain Barrier, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glioma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Peptides, Paclitaxel, Maximum Tolerated Dose, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase I Study of GRN1005 in Recurrent Malignant Glioma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks